Palvella is progressing its drug QTORIN, targeting microcystic lymphatic malformations and other skin diseases, supported by positive Phase 3 SELVA trial results. The company is leveraging a repeatable regulatory and commercial platform to expand QTORIN's use across multiple mTOR-driven dermatological conditions. A recent $230 million equity raise provides strong liquidity, enabling further commercialization and pipeline development. Approval of QTORIN is crucial to justify Palvella's current valuation and unlock future growth potential.
Nuclear energy stocks like Oklo, Constellation Energy, and NuScale Power fell sharply due to concerns over AI-related capital expenditure and a spike in long-term Treasury yields to a 19-year high. AI companies reported lower-than-expected revenue fo...
Worldcoin (WLD) declined 11% in one day, extending its 30-day loss to 14%, driven by increased selling pressure from large holders (whales) and weak on-chain activity. Whale dominance in trading surged, with sell-side volume leading on most exchanges...
Bitcoin's correction phase, lasting over 11 months, might be close to ending according to VanEck's report. Eight out of twelve capitulation indicators are currently signaling seller exhaustion, suggesting a critical liquidation phase is underway. Ins...
Halper Sadeh LLC is investigating whether certain officers and directors of BellRing Brands, Inc. breached their fiduciary duties to shareholders. Long-term BellRing stockholders may seek corporate governance reforms, financial incentives, or other r...
Credit Suisse High Yield Credit Fund will execute a 1-for-10 reverse share split on September 30, 2026, reducing the number of shares while increasing the price per share proportionally. This move aims to improve market liquidity and broaden investor...
